Navigation Links
China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
Date:12/10/2009

for the third quarter of 2009 decreased to $12.4 million, or 70.9% of net revenue, from $7.7 million, or 80.3% in the 2008 third quarter, largely in line with sales decline.

Gross profit for the three months ended September 30, 2009 totaled $3.1 million, or 29.1% of net sales, compared with gross profit of $3.0 million, or 19.7% of net sales, for the same period of 2008. The improvement in gross margin was mainly due to a better sales mix and a focus on higher margin products, including cosmetics and certain health and organic products.

Operating expenses totaled approximately $3.3 million for the third quarter of 2009, up 168.7% from $1.2 million in the third quarter of 2008. As a percentage of net revenue, third-quarter 2009 total operating expenses amounted to 30.4%, compared to third-quarter 2008 operating expenses at 7.9% of net revenue. This was largely attributable to a sharp increase in general and administrative expenses, which more than quintupled in the third quarter, primarily driven by allowance for doubtful accounts for accounts receivable and accrued litigation fees. Selling expenses rose moderately by 6.3% as the Company opened two new retail stores during the third quarter.

Other income amounted to $1.1 million for the three months ended September 30, 2009, an increase of 85.5% from $0.5 million for the same period in 2008, largely due to higher sponsorship and rebates from customers and suppliers in combination with an 87.6% decline in interest expenses.

The Company's net income attributable to common shares during the three months ended September 30, 2009 was $0.5 million down 71.5% from $1.7 million for the three months ended September 30, 2008. In addition to higher operating expenses, third-quarter net income was also negatively affected by a change in the collection of sponsorship fees and rebates from customers and suppliers from an annual basis to a quarterly basis.


'/>"/>
SOURCE China Yongxin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , FRIMLEY, England, December 8 , ... Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on,imatinib 400mg ... Only a Small Number of Patients,Discontinued Due to Adverse Events(1) , ...
... ... , ... - Will Use BrainTrack,s College Campus Data to Enhance Elsevier Evolve,Website Registrations ... technical and,medical information products and services, and BrainTrack,( http://www.braintrack.com ), the widely referenced ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Elsevier Selects BrainTrack Directory as Supplier of College Data 2Elsevier Selects BrainTrack Directory as Supplier of College Data 3Elsevier Selects BrainTrack Directory as Supplier of College Data 4
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... issue of Experimental Biology and Medicine ... Gaskins and Paul Kenis in the Institute of ... University of Illinois Urbana-Champaign describe their recent work ... a variety of cell functions including energy metabolism, ... roles in regulating normal cellular behavior, redox status ...
(Date:4/17/2014)... in the April issue of Immunity , Kevin ... Medical Research, says it,s time to take a fresh ... sepsis, which kills millions worldwide every year, including ... released into the bloodstream to fight an injury or ... for maintaining good health without inflammation, wounds and ...
Breaking Medicine News(10 mins):Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:New pain relief targets discovered 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
... IDXX ), announced today that its Board of ... additional four million,shares of its common stock under its ... open market or in negotiated transactions.,These shares are in ... 2007, under a previous Board authorization. The timing and,amount ...
... Consumer,Healthcare, a division of Wyeth (NYSE: WYE ... named Executive Vice President, Global Research and,Development (R&D), ... the consumer division,s global R&D organization. In her ... R&D efforts to,effectively bring new products to market ...
... Researchers find chronic worry impairs immune response to cancer-causing ... levels of daily stress could explain why some women ... cervical cancer, a new study suggests. , Scientists ... women, all diagnosed with cervical dysplasia (precancerous cervical lesions), ...
... Precious Medicare Dollars on Trial Lawyers and,Focus on Needy ... Blunt (Mo.) today praised President Bush,s proposal that would ... is clear that without substantial reforms, Medicare will not ... The legislation put,forth by the president is the needed ...
... million in bonuses and incentives, ADA, Mich., Feb. ... $1.072 billion, the fifth consecutive year in which the,company ... from the previous year,s sales of $1.12 billion, which ... affected minimally by actions the company took to,terminate the ...
... media outreach for TRIA, the first hair removal ... to enter U.S. home-based beauty device market, NEW ... Rpr Marketing Communications as its U.S. agency of record ... U.S. home-based beauty,device market., SpectraGenics, Inc. is a ...
Cached Medicine News:Health News:Wyeth Consumer Healthcare Names New Head of Global R&D 2Health News:Daily Stress May Raise Women's Risk of Cervical Cancer 2Health News:Daily Stress May Raise Women's Risk of Cervical Cancer 3Health News:Blunt Praises President's Plan to Save Medicare 2Health News:Quixtar Announces Fifth Consecutive Year of Billion-Dollar Sales 2Health News:Spectragenics Names Rpr Marketing Communications Agency of Record 2
Microforceps : Eckardt End & Side Gripping Forceps...
Blunt tipped forceps wlth a small grasping platform on each tip. For grasping fine membranes or grasping membranes adherent to the retinal surface....
Microforceps: Spaid Pic Forceps...
Blunt tipped forceps with small, slightly pointed grasping platforms on each tip. For general purpose (fine) membrane grasping and grasping membranes adherent to the retlnal surface....
Medicine Products: